Triggering of suicidal erythrocyte death by zosuquidar

Cellular Physiology and Biochemistry

Volumn 37, Issue 6, 2015, Pages 2355-2365

  Briglia, Marilena ^a,b   Fazio, Antonella ^a,b   Faggio, Caterina ^b   Lang, Florian ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY OF MESSINA   (Italy)

Author keywords

Calcium; Calphostin; Cell volume; Eryptosis; Phosphatidylserine; SB203580

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; CALPHOSTIN; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHATIDYLSERINE; PROTEIN KINASE C; REACTIVE OXYGEN METABOLITE; ZOSUQUIDAR; CALCIUM; DIBENZO[A,D]CYCLOHEPTENE DERIVATIVE; QUINOLINE DERIVATIVE;

APOPTOSIS; ARTICLE; CELL DEATH; CELL MEMBRANE; CELL SURFACE; CELL VOLUME; CONTROLLED STUDY; ENZYME ACTIVATION; ERYPTOSIS; ERYTHROCYTE; ERYTHROCYTE MEMBRANE; GENE TRANSLOCATION; HUMAN; NORMAL HUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; UPREGULATION; CYTOLOGY; DRUG EFFECTS; FLUORESCENCE; IN VITRO STUDY; METABOLISM;

CALCIUM; CELL DEATH; DIBENZOCYCLOHEPTENES; ERYTHROCYTES; FLUORESCENCE; HUMANS; IN VITRO TECHNIQUES; QUINOLINES;

EID: 84949563014     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000438589     Document Type: Article

References (114)

1. Anderson BD, May MJ, Jordan S, Song L, Roberts MJ, Leggas M. Dependence of nelfinavir brain uptake on dose and tissue concentrations of the selective P-glycoprotein inhibitor zosuquidar in rats. Drug Metab Dispos 2006; 34: 653-659
2. Bates SF, Chen C, Robey R, Kang M, Figg WD, Fojo T. Reversal of multidrug resistance: lessons from clinical oncology. Novartis Found Symp 2002; 243: 83-96; discussion 96-102, 180-105
3. Callies S, de Alwis DP, Harris A, Vasey P, Beijnen JH, Schellens JH, Burgess M, Aarons L A population pharmacokinetic model for paclitaxel in the presence of a novel P-gp modulator, Zosuquidar Trihydrochloride (LY335979). Br J Clin Pharmacol 2003; 56: 46-56
4. Callies S, de Alwis DP, Wright JG, Sandler A, Burgess M, Aarons L A population pharmacokinetic model for doxorubicin and doxorubicinol in the presence of a novel MDR modulator, zosuquidar trihydrochloride (LY335979). Cancer Chemother Pharmacol 2003; 51: 107-118
5. Dantzig AH, Law KL, Cao J, Starling JJ. Reversal of multidrug resistance by the P-glycoprotein modulator, LY335979, from the bench to the clinic. Curr Med Chem 2001; 8: 39-50
6. Kocharyan A, Feldman R, Singleton A, Han X, Bleier BS. P-glycoprotein inhibition promotes prednisone retention in human sinonasal polyp explants. Int Forum Allergy Rhinol 2014; 4: 734-738
7. Lam A, Hoang JD, Singleton A, Han X, Bleier BS. Itraconazole and clarithromycin inhibit P-glycoprotein activity in primary human sinonasal epithelial cells. Int Forum Allergy Rhinol 2015; 5: 477-480
8. Paine MF, Leung LY, Watkins PB. New insights into drug absorption: studies with sirolimus. Ther Drug Monit 2004; 26: 463-467
9. Ross DD. Modulation of drug resistance transporters as a strategy for treating myelodysplastic syndrome. Best Pract Res Clin Haematol 2004; 17: 641-651
10. Thomas H, Coley HM. Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. Cancer Control 2003; 10: 159-165
11. Werle M, Takeuchi H, Bernkop-Schnurch A. New-generation efflux pump inhibitors. Expert Rev Clin Pharmacol 2008; 1: 429-440
12. Abu Ajaj K, Graeser R, Kratz F. Zosuquidar and an albumin-binding prodrug of zosuquidar reverse multidrug resistance in breast cancer cells of doxorubicin and an albumin-binding prodrug of doxorubicin. Breast Cancer Res Treat 2012; 134: 117-129
13. Cnubben NH, Wortelboer HM, van Zanden JJ, Rietjens IM, van Bladeren PJ. Metabolism of ATP-binding cassette drug transporter inhibitors: complicating factor for multidrug resistance. Expert Opin Drug Metab Toxicol 2005; 1: 219-232
14. Cripe LD, Uno H, Paietta EM, Litzow MR, Ketterling RP, Bennett JM, Rowe JM, Lazarus HM, Luger S, Tallman MS. Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999. Blood 2010; 116: 4077-4085
15. Fracasso PM, Goldstein LJ, de Alwis DP, Rader JS, Arquette MA, Goodner SA, Wright LP, Fears CL, Gazak RJ, Andre VA, Burgess MF, Slapak CA, Schellens JH. Phase I study of docetaxel in combination with the P-glycoprotein inhibitor, zosuquidar, in resistant malignancies. Clin Cancer Res 2004; 10: 7220-7228
16. Gerrard G, Payne E, Baker RJ, Jones DT, Potter M, Prentice HG, Ethell M, McCullough H, Burgess M, Mehta AB, Ganeshaguru K. Clinical effects and P-glycoprotein inhibition in patients with acute myeloid leukemia treated with zosuquidar trihydrochloride, daunorubicin and cytarabine. Haematologica 2004; 89: 782-790
17. Lancet JE, Baer MR, Duran GE, List AF, Fielding R, Marcelletti JF, Multani PS, Sikic BI A phase I trial of continuous infusion of the multidrug resistance inhibitor zosuquidar with daunorubicin and cytarabine in acute myeloid leukemia. Leuk Res 2009; 33: 1055-1061
18. Le LH, Moore MJ, Siu LL, Oza AM, MacLean M, Fisher B, Chaudhary A, de Alwis DP, Slapak C, Seymour L. Phase I study of the multidrug resistance inhibitor zosuquidar administered in combination with vinorelbine in patients with advanced solid tumours. Cancer Chemother Pharmacol 2005; 56: 154-160
19. Marcelletti JF, Multani PS, Lancet JE, Baer MR, Sikic BI. Leukemic blast and natural killer cell P-glycoprotein function and inhibition in a clinical trial of zosuquidar infusion in acute myeloid leukemia. Leuk Res 2009; 33: 769-774
20. Morschhauser F, Zinzani PL, Burgess M, Sloots L, Bouafia F, Dumontet C. Phase I/II trial of a P-glycoprotein inhibitor, Zosuquidar.3HCl trihydrochloride (LY335979), given orally in combination with the CHOP regimen in patients with non-Hodgkin's lymphoma. Leuk Lymphoma 2007; 48: 708-715
21. Nobili S, Landini I, Giglioni B, Mini E. Pharmacological strategies for overcoming multidrug resistance. Curr Drug Targets 2006; 7: 861-879
22. Robak T, Szmigielska-Kaplon A, Pluta A, Grzybowska-Izydorczyk O, Wolska A, Czemerska M, Wierzbowska A. Novel and emerging drugs for acute myeloid leukemia: pharmacology and therapeutic activity. Curr Med Chem 2011; 18: 638-666
23. Rubin EH, de Alwis DP, Pouliquen I, Green L, Marder P, Lin Y, Musanti R, Grospe SL, Smith SL, Toppmeyer DL, Much J, Kane M, Chaudhary A, Jordan C, Burgess M, Slapak CA A phase I trial of a potent P-glycoprotein inhibitor, Zosuquidar.3HCl trihydrochloride (LY335979), administered orally in combination with doxorubicin in patients with advanced malignancies. Clin Cancer Res 2002; 8: 3710-3717
24. Ruff P, Vorobiof DA, Jordaan JP, Demetriou GS, Moodley SD, Nosworthy AL, Werner ID, Raats J, Burgess LJ A randomized, placebo-controlled, double-blind phase 2 study of docetaxel compared to docetaxel plus zosuquidar (LY335979) in women with metastatic or locally recurrent breast cancer who have received one prior chemotherapy regimen. Cancer Chemother Pharmacol 2009; 64: 763-768
25. Sandler A, Gordon M, De Alwis DP, Pouliquen I, Green L, Marder P, Chaudhary A, Fife K, Battiato L, Sweeney C, Jordan C, Burgess M, Slapak CA A Phase I trial of a potent P-glycoprotein inhibitor, zosuquidar trihydrochloride (LY335979), administered intravenously in combination with doxorubicin in patients with advanced malignancy. Clin Cancer Res 2004; 10: 3265-3272
26. Tang R, Faussat AM, Perrot JY, Marjanovic Z, Cohen S, Storme T, Morjani H, Legrand O, Marie JP. Zosuquidar restores drug sensitivity in P-glycoprotein expressing acute myeloid leukemia (AML). BMC Cancer 2008; 8: 51
27. Bihorel S, Camenisch G, Lemaire M, Scherrmann JM. Modulation of the brain distribution of imatinib and its metabolites in mice by valspodar, zosuquidar and elacridar. Pharm Res 2007; 24: 1720-1728
28. Hermann DM, Kilic E, Spudich A, Kramer SD, Wunderli-Allenspach H, Bassetti CL. Role of drug efflux carriers in the healthy and diseased brain. Ann Neurol 2006; 60: 489-498
29. Kemper EM, Cleypool C, Boogerd W, Beijnen JH, van Tellingen O. The influence of the P-glycoprotein inhibitor zosuquidar trihydrochloride (LY335979) on the brain penetration of paclitaxel in mice. Cancer Chemother Pharmacol 2004; 53: 173-178
30. Infed N, Smits SH, Dittrich T, Braun M, Driessen AJ, Hanekop N, Schmitt L. Analysis of the inhibition potential of zosuquidar derivatives on selected bacterial and fungal ABC transporters. Mol Membr Biol 2013; 30: 217-227
31. Lehne G, De Angelis P, den Boer M, Rugstad HE. Growth inhibition, cytokinesis failure and apoptosis of multidrug-resistant leukemia cells after treatment with P-glycoprotein inhibitory agents. Leukemia 1999; 13: 768-778
32. Tang R, Cohen S, Perrot JY, Faussat AM, Zuany-Amorim C, Marjanovic Z, Morjani H, Fava F, Corre E, Legrand O, Marie JP. P-gp activity is a critical resistance factor against AVE9633 and DM4 cytotoxicity in leukaemia cell lines, but not a major mechanism of chemoresistance in cells from acute myeloid leukaemia patients. BMC Cancer 2009; 9: 199
33. Lang PA, Kaiser S, Myssina S, Wieder T, Lang F, Huber SM. Role of Ca2+-Activated K+ channels in human erythrocyte apoptosis. Am J Physiol Cell Physiol 2003; 285: C1553-C1560
34. Lang E, Qadri SM, Lang F. Killing me softly-suicidal erythrocyte death. Int J Biochem Cell Biol 2012; 44: 1236-1243
35. Lancet JE, Baer MR, Duran GE, List AF, Fielding R, Marcelletti JF, Multani PS, Sikic BI A phase I trial of continuous infusion of the multidrug resistance inhibitor zosuquidar with daunorubicin and cytarabine in acute myeloid leukemia. Leuk Res 2009; 33: 1055-1061
36. Le LH, Moore MJ, Siu LL, Oza AM, MacLean M, Fisher B, Chaudhary A, de Alwis DP, Slapak C, Seymour L. Phase I study of the multidrug resistance inhibitor zosuquidar administered in combination with vinorelbine in patients with advanced solid tumours. Cancer Chemother Pharmacol 2005; 56: 154-160
37. Marcelletti JF, Multani PS, Lancet JE, Baer MR, Sikic BI. Leukemic blast and natural killer cell P-glycoprotein function and inhibition in a clinical trial of zosuquidar infusion in acute myeloid leukemia. Leuk Res 2009; 33: 769-774
38. Morschhauser F, Zinzani PL, Burgess M, Sloots L, Bouafia F, Dumontet C. Phase I/II trial of a P-glycoprotein inhibitor, Zosuquidar.3HCl trihydrochloride (LY335979), given orally in combination with the CHOP regimen in patients with non-Hodgkin's lymphoma. Leuk Lymphoma 2007; 48: 708-715
39. Nobili S, Landini I, Giglioni B, Mini E. Pharmacological strategies for overcoming multidrug resistance. Curr Drug Targets 2006; 7: 861-879
40. Robak T, Szmigielska-Kaplon A, Pluta A, Grzybowska-Izydorczyk O, Wolska A, Czemerska M, Wierzbowska A. Novel and emerging drugs for acute myeloid leukemia: pharmacology and therapeutic activity. Curr Med Chem 2011; 18: 638-666
41. Rubin EH, de Alwis DP, Pouliquen I, Green L, Marder P, Lin Y, Musanti R, Grospe SL, Smith SL, Toppmeyer DL, Much J, Kane M, Chaudhary A, Jordan C, Burgess M, Slapak CA A phase I trial of a potent P-glycoprotein inhibitor, Zosuquidar.3HCl trihydrochloride (LY335979), administered orally in combination with doxorubicin in patients with advanced malignancies. Clin Cancer Res 2002; 8: 3710-3717
42. Ruff P, Vorobiof DA, Jordaan JP, Demetriou GS, Moodley SD, Nosworthy AL, Werner ID, Raats J, Burgess LJ A randomized, placebo-controlled, double-blind phase 2 study of docetaxel compared to docetaxel plus zosuquidar (LY335979) in women with metastatic or locally recurrent breast cancer who have received one prior chemotherapy regimen. Cancer Chemother Pharmacol 2009; 64: 763-768
43. Sandler A, Gordon M, De Alwis DP, Pouliquen I, Green L, Marder P, Chaudhary A, Fife K, Battiato L, Sweeney C, Jordan C, Burgess M, Slapak CA A Phase I trial of a potent P-glycoprotein inhibitor, zosuquidar trihydrochloride (LY335979), administered intravenously in combination with doxorubicin in patients with advanced malignancy. Clin Cancer Res 2004; 10: 3265-3272
44. Tang R, Faussat AM, Perrot JY, Marjanovic Z, Cohen S, Storme T, Morjani H, Legrand O, Marie JP. Zosuquidar restores drug sensitivity in P-glycoprotein expressing acute myeloid leukemia (AML). BMC Cancer 2008; 8: 51
45. Bihorel S, Camenisch G, Lemaire M, Scherrmann JM. Modulation of the brain distribution of imatinib and its metabolites in mice by valspodar, zosuquidar and elacridar. Pharm Res 2007; 24: 1720-1728
46. Hermann DM, Kilic E, Spudich A, Kramer SD, Wunderli-Allenspach H, Bassetti CL. Role of drug efflux carriers in the healthy and diseased brain. Ann Neurol 2006; 60: 489-498
47. Kemper EM, Cleypool C, Boogerd W, Beijnen JH, van Tellingen O. The influence of the P-glycoprotein inhibitor zosuquidar trihydrochloride (LY335979) on the brain penetration of paclitaxel in mice. Cancer Chemother Pharmacol 2004; 53: 173-178
48. Infed N, Smits SH, Dittrich T, Braun M, Driessen AJ, Hanekop N, Schmitt L. Analysis of the inhibition potential of zosuquidar derivatives on selected bacterial and fungal ABC transporters. Mol Membr Biol 2013; 30: 217-227
49. Lehne G, De Angelis P, den Boer M, Rugstad HE. Growth inhibition, cytokinesis failure and apoptosis of multidrug-resistant leukemia cells after treatment with P-glycoprotein inhibitory agents. Leukemia 1999; 13: 768-778
50. Tang R, Cohen S, Perrot JY, Faussat AM, Zuany-Amorim C, Marjanovic Z, Morjani H, Fava F, Corre E, Legrand O, Marie JP. P-gp activity is a critical resistance factor against AVE9633 and DM4 cytotoxicity in leukaemia cell lines, but not a major mechanism of chemoresistance in cells from acute myeloid leukaemia patients. BMC Cancer 2009; 9: 199
51. Lang PA, Kaiser S, Myssina S, Wieder T, Lang F, Huber SM. Role of Ca2+-Activated K+ channels in human erythrocyte apoptosis. Am J Physiol Cell Physiol 2003; 285: C1553-C1560
52. Lang E, Qadri SM, Lang F. Killing me softly-suicidal erythrocyte death. Int J Biochem Cell Biol 2012; 44: 1236-1243
53. Abed M, Towhid ST, Mia S, Pakladok T, Alesutan I, Borst O, Gawaz M, Gulbins E, Lang F. Sphingomyelinaseinduced adhesion of eryptotic erythrocytes to endothelial cells. Am J Physiol Cell Physiol 2012; 303: C991-999
54. Lau IP, Chen H, Wang J, Ong HC, Leung KC, Ho HP, Kong SK. In vitro effect of CTAB-And PEG-coated gold nanorods on the induction of eryptosis/erythroptosis in human erythrocytes. Nanotoxicology 2012; 6: 847-856
55. Maellaro E, Leoncini S, Moretti D, Del Bello B, Tanganelli I, De Felice C, Ciccoli L. Erythrocyte caspase-3 activation and oxidative imbalance in erythrocytes and in plasma of type 2 diabetic patients. Acta Diabetol 2013; 50: 489-495
56. Bottger E, Multhoff G, Kun JF, Esen M. Plasmodium falciparum-infected erythrocytes induce granzyme B by NK cells through expression of host-Hsp70. PLoS One 2012; 7: e33774
57. Firat U, Kaya S, Cim A, Buyukbayram H, Gokalp O, Dal MS, Tamer MN. Increased caspase-3 immunoreactivity of erythrocytes n STZ diabetic rats. Exp Diabetes Res 2012; 2012: 316384
58. Ganesan S, Chaurasiya ND, Sahu R, Walker LA, Tekwani BL. Understanding the mechanisms for metabolism-linked hemolytic toxicity of primaquine against glucose 6-phosphate dehydrogenase deficient human erythrocytes: evaluation of eryptotic pathway. Toxicology 2012; 294: 54-60
59. Gao M, Cheung KL, Lau IP, Yu WS, Fung KP, Yu B, Loo JF, Kong SK. Polyphyllin D induces apoptosis in human erythrocytes through Ca(2)(+) rise and membrane permeabilization. Arch Toxicol 2012; 86: 741-752
60. Ghashghaeinia M, Cluitmans JC, Akel A, Dreischer P, Toulany M, Koberle M, Skabytska Y, Saki M, Biedermann T, Duszenko M, Lang F, Wieder T, Bosman GJ. The impact of erythrocyte age on eryptosis. Br J Haematol 2012; 157: 606-614
61. Jilani K, Qadri SM, Lang F. Geldanamycin-induced phosphatidylserine translocation in the erythrocyte membrane. Cell Physiol Biochem 2013; 32: 1600-1609
62. Polak-Jonkisz D, Purzyc L. Ca Influx versus Efflux during Eryptosis in Uremic Erythrocytes. Blood Purif 2012; 34: 209-210
63. Qian EW, Ge DT, Kong SK. Salidroside protects human erythrocytes against hydrogen peroxide-induced apoptosis. J Nat Prod 2012; 75: 531-537
64. Vota DM, Maltaneri RE, Wenker SD, Nesse AB, Vittori DC. Differential erythropoietin action upon cells induced to eryptosis by different agents. Cell Biochem Biophys 2013; 65: 145-157
65. Weiss E, Cytlak UM, Rees DC, Osei A, Gibson JS. Deoxygenation-induced and Ca(2+) dependent phosphatidylserine externalisation in red blood cells from normal individuals and sickle cell patients. Cell Calcium 2012; 51: 51-56
66. Zappulla D. Environmental stress, erythrocyte dysfunctions, inflammation, and the metabolic syndrome: adaptations to CO2 increases?. J Cardiometab Syndr 2008; 3: 30-34
67. Zbidah M, Lupescu A, Jilani K, Lang F. Stimulation of suicidal erythrocyte death by fumagillin. Basic Clin Pharmacol Toxicol 2013; 112: 346-351
68. Ahmed MS, Langer H, Abed M, Voelkl J, Lang F. The uremic toxin acrolein promotes suicidal erythrocyte death. Kidney Blood Press Res 2013; 37: 158-167
69. Ghashghaeinia M, Cluitmans JC, Toulany M, Saki M, Koberle M, Lang E, Dreischer P, Biedermann T, Duszenko M, Lang F, Bosman GJ, Wieder T. Age Sensitivity of NFkappaB Abundance and Programmed Cell Death in Erythrocytes Induced by NFkappaB Inhibitors. Cell Physiol Biochem 2013; 32: 801-813
70. Alzoubi K, Honisch S, Abed M, Lang F. Triggering of Suicidal Erythrocyte Death by Penta-O-galloyl-beta-dglucose. Toxins (Basel) 2014; 6: 54-65
71. Jilani K, Enkel S, Bissinger R, Almilaji A, Abed M, Lang F. Fluoxetine induced suicidal erythrocyte death. Toxins (Basel) 2013; 5: 1230-1243
72. Lupescu A, Bissinger R, Jilani K, Lang F. Triggering of suicidal erythrocyte death by celecoxib. Toxins (Basel) 2013; 5: 1543-1554
73. Lupescu A, Jilani K, Zbidah M, Lang F. Patulin-induced suicidal erythrocyte death. Cell Physiol Biochem 2013; 32: 291-299
74. Abed M, Zoubi KA, Theurer M, Lang F. Effect of dermaseptin on erythrocytes. Basic Clin Pharmacol Toxicol 2013; 113: 347-352
75. Arnold M, Lang E, Modicano P, Bissinger R, Faggio C, Abed M, Lang F. Effect of nitazoxanide on erythrocytes. Basic Clin Pharmacol Toxicol 2014; 114: 421-426
76. Oswald G, Alzoubi K, Abed M, Lang F. Stimulation of suicidal erythrocyte death by ribavirin. Basic Clin Pharmacol Toxicol 2014; 114: 311-317
77. Jacobi J, Lang E, Bissinger R, Frauenfeld L, Modicano P, Faggio C, Abed M, Lang F. Stimulation of erythrocyte cell membrane scrambling by mitotane. Cell Physiol Biochem 2014; 33: 1516-1526
78. Lupescu A, Bissinger R, Warsi J, Jilani K, Lang F. Stimulation of erythrocyte cell membrane scrambling by gedunin. Cell Physiol Biochem 2014; 33: 1838-1848
79. Abed M, Feger M, Alzoubi K, Pakladok T, Frauenfeld L, Geiger C, Towhid ST, Lang F. Sensitization of erythrocytes to suicidal erythrocyte death following water deprivation. Kidney Blood Press Res 2013; 37: 567-578
80. Alzoubi K, Calabro S, Bissinger R, Abed M, Faggio C, Lang F. Stimulation of suicidal erythrocyte death by artesunate. Cell Physiol Biochem 2014; 34: 2232-2244
81. Arnold M, Bissinger R, Lang F. Mitoxantrone-induced suicidal erythrocyte death. Cell Physiol Biochem 2014; 34: 1756-1767
82. Bissinger R, Fischer S, Jilani K, Lang F. Stimulation of erythrocyte death by phloretin. Cell Physiol Biochem 2014; 34: 2256-2265
83. Bissinger R, Lupescu A, Zelenak C, Jilani K, Lang F. Stimulation of eryptosis by cryptotanshinone. Cell Physiol Biochem 2014; 34: 432-442
84. Bissinger R, Modicano P, Frauenfeld L, Lang E, Jacobi J, Faggio C, Lang F. Estramustine-induced suicidal erythrocyte death. Cell Physiol Biochem 2013; 32: 1426-1436
85. Malik A, Bissinger R, Calabro S, Faggio C, Jilani K, Lang F. Aristolochic acid induced suicidal erythrocyte death. Kidney Blood Press Res 2014; 39: 408-419
86. Tesoriere L, Attanzio A, Allegra M, Cilla A, Gentile C, Livrea MA. Oxysterol mixture in hypercholesterolemiarelevant proportion causes oxidative stress-dependent eryptosis. Cell Physiol Biochem 2014; 34: 1075-1089
87. Voelkl J, Alzoubi K, Mamar AK, Ahmed MS, Abed M, Lang F. Stimulation of suicidal erythrocyte death by increased extracellular phosphate concentrations. Kidney Blood Press Res 2013; 38: 42-51
88. Zhang R, Xiang Y, Ran Q, Deng X, Xiao Y, Xiang L, Li Z. Involvement of calcium, reactive oxygen species, and ATP in hexavalent chromium-induced damage in red blood cells. Cell Physiol Biochem 2014; 34: 1780-1791
89. Lupescu A, Bissinger R, Herrmann T, Oswald G, Jilani K, Lang F. Induction of suicidal erythrocyte death by novobiocin. Cell Physiol Biochem 2014; 33: 670-680
90. Risso A, Ciana A, Achilli C, Minetti G. Survival and senescence of human young red cells in vitro. Cell Physiol Biochem 2014; 34: 1038-1049
91. Zidova Z, Kapralova K, Koralkova P, Mojzikova R, Dolezal D, Divoky V, Horvathova M. DMT1-mutant erythrocytes have shortened life span, accelerated glycolysis and increased oxidative stress. Cell Physiol Biochem 2014; 34: 2221-2231
92. Kemper EM, Ouwehand M, Beijnen JH, van Tellingen O. Bioanalysis of zosuquidar trihydrochloride (LY335979) in small volumes of human and murine plasma by ion-pairing reversed-phase highperformance liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci 2003; 798: 63-68
93. Callies S, de Alwis DP, Mehta A, Burgess M, Aarons L. Population pharmacokinetic model for daunorubicin and daunorubicinol coadministered with zosuquidar.3HCl (LY335979). Cancer Chemother Pharmacol 2004; 54: 39-48
94. Qadri SM, Mahmud H, Lang E, Gu S, Bobbala D, Zelenak C, Jilani K, Siegfried A, Foller M, Lang F. Enhanced suicidal erythrocyte death in mice carrying a loss-of-function mutation of the adenomatous polyposis coli gene. J Cell Mol Med 2012; 16: 1085-1093
95. Lang E, Gatidis S, Freise NF, Bock H, Kubitz R, Lauermann C, Orth HM, Klindt C, Schuier M, Keitel V, Reich M, Liu G, Schmidt S, Xu HC, Qadri SM, Herebian D, Pandyra AA, Mayatepek E, Gulbins E, Lang F, Haussinger D, Lang KS, Foller M, Lang PA. Conjugated bilirubin triggers anemia by inducing erythrocyte death. Hepatology 2015; 61: 275-284
96. Calderon-Salinas JV, Munoz-Reyes EG, Guerrero-Romero JF, Rodriguez-Moran M, Bracho-Riquelme RL, Carrera-Gracia MA, Quintanar-Escorza MA. Eryptosis and oxidative damage in type 2 diabetic mellitus patients with chronic kidney disease. Mol Cell Biochem 2011; 357: 171-179
97. Nicolay J P, Schneider J, Niemoeller OM, Artunc F, Portero-Otin M, Haik G, Jr., Thornalley PJ, Schleicher E, Wieder T, Lang F. Stimulation of suicidal erythrocyte death by methylglyoxal. Cell Physiol Biochem 2006; 18: 223-232
98. Abed M, Artunc F, Alzoubi K, Honisch S, Baumann D, Foller M, Lang F. Suicidal erythrocyte death in endstage renal disease. J Mol Med (Berl) 2014; 92: 871-879
99. Lang PA, Beringer O, Nicolay JP, Amon O, Kempe DS, Hermle T, Attanasio P, Akel A, Schafer R, Friedrich B, Risler T, Baur M, Olbricht CJ, Zimmerhackl LB, Zipfel PF, Wieder T, Lang F. Suicidal death of erythrocytes in recurrent hemolytic uremic syndrome. J Mol Med (Berl) 2006; 84: 378-388
100. Kempe DS, Akel A, Lang PA, Hermle T, Biswas R, Muresanu J, Friedrich B, Dreischer P, Wolz C, Schumacher U, Peschel A, Gotz F, Doring G, Wieder T, Gulbins E, Lang F. Suicidal erythrocyte death in sepsis. J Mol Med (Berl) 2007; 85: 273-281
101. Foller M, Braun M, Qadri SM, Lang E, Mahmud H, Lang F. Temperature sensitivity of suicidal erythrocyte death. Eur J Clin Invest 2010; 40: 534-540
102. Felder KM, Hoelzle K, Ritzmann M, Kilchling T, Schiele D, Heinritzi K, Groebel K, Hoelzle LE. Hemotrophic mycoplasmas induce programmed cell death in red blood cells. Cell Physiol Biochem 2011; 27: 557-564
103. Lang PA, Kasinathan RS, Brand VB, Duranton C, Lang C, Koka S, Shumilina E, Kempe DS, Tanneur V, Akel A, Lang KS, Foller M, Kun JF, Kremsner PG, Wesselborg S, Laufer S, Clemen CS, Herr C, Noegel AA, Wieder T, Gulbins E, Lang F, Huber SM. Accelerated clearance of Plasmodium-infected erythrocytes in sickle cell trait and annexin-A7 deficiency. Cell Physiol Biochem 2009; 24: 415-428
104. Kempe DS, Lang PA, Duranton C, Akel A, Lang KS, Huber SM, Wieder T, Lang F. Enhanced programmed cell death of iron-deficient erythrocytes. FASEB J 2006; 20: 368-370
105. Lang KS, Roll B, Myssina S, Schittenhelm M, Scheel-Walter HG, Kanz L, Fritz J, Lang F, Huber SM, Wieder T. Enhanced erythrocyte apoptosis in sickle cell anemia, thalassemia and glucose-6-phosphate dehydrogenase deficiency. Cell Physiol Biochem 2002; 12: 365-372
106. Lang PA, Schenck M, Nicolay JP, Becker JU, Kempe DS, Lupescu A, Koka S, Eisele K, Klarl BA, Rubben H, Schmid KW, Mann K, Hildenbrand S, Hefter H, Huber SM, Wieder T, Erhardt A, Haussinger D, Gulbins E, Lang F. Liver cell death and anemia in Wilson disease involve acid sphingomyelinase and ceramide. Nat Med 2007; 13: 164-170
107. Borst O, Abed M, Alesutan I, Towhid ST, Qadri SM, Foller M, Gawaz M, Lang F. Dynamic adhesion of eryptotic erythrocytes to endothelial cells via CXCL16/SR-PSOX. Am J Physiol Cell Physiol 2012; 302: C644-C651
108. Andrews DA, Low PS. Role of red blood cells in thrombosis. Curr Opin Hematol 1999; 6: 76-82
109. Chung SM, Bae ON, Lim KM, Noh JY, Lee MY, Jung YS, Chung JH. Lysophosphatidic acid induces thrombogenic activity through phosphatidylserine exposure and procoagulant microvesicle generation i human erythrocytes. Arterioscler Thromb Vasc Biol 2007; 27: 414-421
110. Zwaal RF, Comfurius P, Bevers EM. Surface exposure of phosphatidylserine in pathological cells. Cell Mol Life Sci 2005; 62: 971-988
111. Closse C, Dachary-Prigent J, Boisseau MR. Phosphatidylserine-related adhesion of human erythrocytes to vascular endothelium. Br J Haematol 1999; 107: 300-302
112. Gallagher PG, Chang SH, Rettig M P, Neely JE, Hillery CA, Smith BD, Low PS. Altered erythrocyte endothelial adherence and membrane phospholipid asymmetry in hereditary hydrocytosis. Blood 2003; 101: 4625-4627
113. Pandolfi A, Di Pietro N, Sirolli V, Giardinelli A, Di Silvestre S, Amoroso L, Di Tomo P, Capani F, Consoli A, Bonomini M. Mechanisms of uremic erythrocyte-induced adhesion of human monocytes to cultured endothelial cells. J Cell Physiol 2007; 213: 699-709
114. Wood BL, Gibson DF, Tait JF. Increased erythrocyte phosphatidylserine exposure in sickle cell disease: flowcytometric measurement and clinical associations. Blood 1996; 88: 1873-1880